Can we select NSCLC patients for immune checkpoint therapy?

16 / 38

Impact of TMB on anti-PD-1
Carbone – NEJM 2017
HIGH TMB
LOW TMB
PFS in CheckMate026 phase III trial
OS was similar between groups regardless of TMB (~68% crossover)
<100 mut
≥ 243 mut